Streetbeat News

Stock Prices

KEYS

Keysight Technologies (KEYS) reported Q1 earnings of $1.63 per share, surpassing the $1.59 estimate, and sales of $1.26B, exceeding the $1.25B estimate. However, this represents a 19.31% decrease in earnings and an 8.83% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:06 pm

RNG

RingCentral (NYSE:RNG) reported Q4 2023 adjusted EPS of $0.86, surpassing the $0.82 estimate, with sales of $571.00M exceeding the $570.42M estimate. This represents an 8.81% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:06 pm

WSC

WillScot Mobile Mini (NASDAQ:WSC) reported Q4 earnings of $0.44 per share, missing the consensus estimate of $0.52, and sales of $612.38M, missing the estimate of $619.90M. This represents a decrease in earnings and an increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:05 pm

HALO

Halozyme Therapeutics (NASDAQ:HALO) reported Q4 earnings with an EPS of $0.82, missing the estimate of $0.83 by 1.2%. Revenue increased by $48.54 million from the same period last year. In the previous quarter, HALO beat the EPS estimate by $0.02, leading to a 10.04% share price increase the next day.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:05 pm

FLS

Flowserve (NYSE:FLS) reported Q4 earnings with an EPS of $0.68, beating estimates by 13.33% and showing a revenue increase of $126M from the previous year. This follows a pattern of surpassing EPS estimates in previous quarters, with a notable 4.1% share price increase after last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:05 pm

FANG

Diamondback Energy (NASDAQ:FANG) reported Q4 adjusted earnings of $4.74 per share, surpassing the consensus estimate of $4.66. Quarterly sales reached $2.23 billion, exceeding the $2.17 billion estimate and marking a 9.75% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:03 pm

HALO

Halozyme Therapeutics (NASDAQ:HALO) reported Q4 adjusted EPS of $0.82, missing the $0.83 estimate, and sales of $230.04M, missing the $233.19M estimate. This represents a 70.83% increase in earnings and a 26.75% increase in sales from the same period last year.

Portfolio Pulse from saritha@benzinga.com

February 20, 2024 | 9:03 pm

CZR

Caesars Entertainment (CZR) reported Q4 2023 GAAP EPS of $(0.34), missing the $(0.07) estimate by 385.71%. Quarterly sales were $2.83 billion, slightly below the $2.85 billion estimate, marking a 0.32% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:02 pm

CZR

Caesars Entertainment (NASDAQ:CZR) reported Q4 sales of $2.83 billion, missing the analyst consensus estimate of $2.85 billion by 0.68%. This represents a 0.32% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:01 pm

PHXM

Trading for PHXM was halted at 4:01:00 p.m. ET due to pending news. The halt is a temporary measure awaiting the release of significant information.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:01 pm